Auto/Allo, Biospecific, CAR T (ABC) Tumor Board - 10/23/2025

Thursday, October 23, 2025, 1:00 PM - 2:00 PM, Rutgers Cancer Institute, New Brunswick, NJ

Provided by Rutgers Cancer Institute

Objective(s): 1 Demonstrate an improved understanding of cellular therapies for blood cancers. 2 Describe recent advances in cellular therapies and their clinical implications. 3 Evaluate and select appropriate cellular therapies for specific patient cases, comparing them with alternative treatment options. 4 Analyze the safety profiles of cellular therapies in comparison to other treatment modalities. 5 Identify and apply alternative strategies to enhance patient outcomes and quality of life.
Location: Rutgers Cancer Institute

Faculty Disclosures:
Emma Rabinovich, MD (Nothing to disclose - 08/01/2025)
Dale G. Schaar, MD (Nothing to disclose - 05/28/2025)
Mansi R Shah, MD (Consultant-Johnson & Johnson|Grant/research support-Janssen Pharmaceuticals|Consultant-Bristol Myers Squibb|Grant/research support-Bristol Myers Squibb|Grant/research support-Regeneron Pharmaceuticals|Consultant-Regeneron Pharmaceuticals (Relationship has ended)|Grant/research support-AbbVie|Paid Speaker-Johnson & Johnson|Consultant-Pfizer - 05/28/2025)
Ogechukwu Egini, MD, MS (Nothing to disclose - 09/14/2025)
Nicole McEntee, MSN (Member, Advisory Board-Bristol Myers Squibb (Relationship has ended) - 10/07/2025)
Download Handout

1. Demonstrate an improved understanding of cellular therapies for blood cancers.
2. Describe recent advances in cellular therapies and their clinical implications.
3. Evaluate and select appropriate cellular therapies for specific patient cases, comparing them with alternative treatment options.
4. Analyze the safety profiles of cellular therapies in comparison to other treatment modalities.
5. Identify and apply alternative strategies to enhance patient outcomes and quality of life.

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Contact: Raquel Mercado - [email protected]; Shanae Williams - [email protected]; Lisette Martinez - [email protected]; Lauren Farer - [email protected]

AMA PRA Category 1 Credits™ (1.00 hours), ACPE Credits (1.00 hours), ANCC Contact Hours (1.00 hours), Non-Physician Attendance (1.00 hours)

Date	Empty Column	Title
10/23/2025 1:00:00 PM	Auto/Allo, Biospecific, CAR T (ABC) Tumor Board - 10/23/2025 10/23/2025 1:00:00 PM 10/23/2025 2:00:00 PM 15 Rutgers Cancer Institute False MM/DD/YYYY	Auto/Allo, Biospecific, CAR T (ABC) Tumor Board - 10/23/2025 Provided by Rutgers Cancer Institute Objective(s): 1 Demonstrate an improved understanding of cellular therapies for blood cancers. 2 Describe recent advances in cellular therapies and their clinical implications. 3 Evaluate and select appropriate cellular therapies for specific patient cases, comparing them with alternative treatment options. 4 Analyze the safety profiles of cellular therapies in comparison to other treatment modalities. 5 Identify and apply alternative strategies to enhance patient outcomes and quality of life. Location: Rutgers Cancer Institute Faculty Disclosures: Emma Rabinovich, MD (Nothing to disclose - 08/01/2025) Dale G. Schaar, MD (Nothing to disclose - 05/28/2025) Mansi R Shah, MD (Consultant-Johnson & Johnson|Grant/research support-Janssen Pharmaceuticals|Consultant-Bristol Myers Squibb|Grant/research support-Bristol Myers Squibb|Grant/research support-Regeneron Pharmaceuticals|Consultant-Regeneron Pharmaceuticals (Relationship has ended)|Grant/research support-AbbVie|Paid Speaker-Johnson & Johnson|Consultant-Pfizer - 05/28/2025) Ogechukwu Egini, MD, MS (Nothing to disclose - 09/14/2025) Nicole McEntee, MSN (Member, Advisory Board-Bristol Myers Squibb (Relationship has ended) - 10/07/2025) Download Handout Location: Rutgers Cancer Institute